Transdermal estrogens in the changing landscape of hormone replacement therapy

  title={Transdermal estrogens in the changing landscape of hormone replacement therapy},
  author={Keli Beck and Michelle Chernikoff Anderson and Julienne K. Kirk},
  journal={Postgraduate Medicine},
  pages={632 - 636}
ABSTRACT Views and clinical practice on hormone replacement therapy (HRT) for postmenopausal women have varied widely over the last several decades. The 1990s showed a dramatic decline in prescribing and only recently are prescription rates increasing again. Use of HRT is first line for women suffering from the symptoms of menopause. For a certain population of postmenopausal women, HRT is recommended for prevention of fracture. More consideration is being given to patient risk factors, side… 
7 Citations
The effect of estroprogestagen therapy on lipid status in menopause depending on the drug administration route
MHT introduced in time, regardless of the route of administration, has beneficial effects on the lipid status, thereby preventing numerous cardiovascular diseases that are the leading cause of mortality.
Biochemical Changes During the First Year of Feminizing Hormone Therapy in Transfeminine Individuals.
Plans to expand the target levels of plasma estradiol concentrations during FHT could be expanded, making the wanted physiological changes easier to obtain, after 11 months of FHT.
Repurposing sex steroids and related drugs as potential treatment for Parkinson's disease
The protective effect of sex hormones, particularly estrogens, progesterone, androgens and dehydroepiandrosterone, in animal models of PD and also in human studies are reviewed to support that drugs affecting estrogen neurotransmission or affecting steroid metabolism with 5&agr;‐reductase inhibitors could be repositioned for treatment of PD.
The use and discontinuation of hormone replacement therapy in women in South China
  • K. Chu, Y. Song, +5 authors J. Zhou
  • Medicine
    Climacteric : the journal of the International Menopause Society
  • 2018
The duration of HRT use in women in south China was short, and a high proportion of the women discontinued HRT, suggesting Chinese health-care providers still have much to do to let women know about the advantages and disadvantages ofHRT and to encourage the use of H RT appropriately.
Monitoring and maintaining bone health in patients with Turner syndrome
Early initiation of estrogen replacement therapy between 11–12 years of age, prompt titration to the adult dose after 2 years, and long-term follow-up to guarantee compliance with ERT, are the key points of osteoporosis prevention in women with TS.
Transdermal estradiol as a novel off-label treatment for Peyronie’s disease: A case report
INTRODUCTION Peyronie’s disease (PD), a condition affecting up to 9% of men, is an abnormal curvature of the penis caused by excessive deposition of fibroid plaques in the tunica albuginea (1, 2).
Hepatic focal nodular hyperplasia after pediatric hematopoietic stem cell transplantation: The impact of hormonal replacement therapy and iron overload
The advent of techniques for the assessment of iron overload (liver T2*‐MRI) has led to the awareness that focal nodular hyperplasia (FNH) represents a possible incidental finding after hematopoietic


Transdermal hormone therapy in postmenopausal women: A review of metabolic effects and drug delivery technologies
Evidence suggests that oral delivery may lead to some undesirable physiologic effects caused by significant gut and hepatic metabolism, so consideration should be given to the route of administration to best suit the needs of the patient.
Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.
While all types of hormone replacement therapies are safe and effective and confer significant benefits in the long-term when initiated in young postmenopausal women, in specific clinical settings the choice of the transdermal route of administration of estrogens and the use of natural progesterone might offer significant benefits and added safety.
Menopausal hormone therapy.
  • B. Bhavnani, R. Strickler
  • Medicine
    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC
  • 2005
Solid, consistent evidence based on observational, epidemiologic, and randomized controlled trials underpins the efficacy of menopausal HT for its regulatory agency-approved indications: vasomotor symptoms, vulvovaginal atrophy symptoms, and osteoporosis-related fracture prevention.
Are all estrogens created equal? A review of oral vs. transdermal therapy.
Significant differences appear to exist between oral and transdermal estrogens in terms of hormonal bioavailability and metabolism, with implications for clinical efficacy, potential side effects, and risk profile of different hormone therapy options, but neither results nor study designs are uniform.
Clinical Pharmacology and Differential Cognitive Efficacy of Estrogen Preparations
Basic clinical pharmacology of various forms of estrogen, neuroendocrinology of the menopause, neurobiology of estradiol and estrone, and results of selected basic science and human intervention studies with relevance to identifying the best form and route of administration of estrogen are discussed.
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.
The use of conjugated equine estrogen (CEE) increases the risk of stroke, decreases therisk of hip fracture, and does not affect CHD incidence in postmenopausal women with prior hysterectomy over an average of 6.8 years, indicating no overall benefit.
Hormone Therapy for Relieving Postmenopausal Vasomotor Symptoms: A Systematic Review.
Low-dose oral and transdermal estrogen in all dose ranges were more likely than placebo to decrease the frequency of VMS and the nanostructured formulation was safe and effective in relieving the symptoms of menopause.
Hormone therapy to prevent disease and prolong life in postmenopausal women
There is evidence that estrogen therapy decreases risk for coronary heart disease and for hip fracture, but long-term estrogen therapy increases risk for endometrial cancer and may be associated with a small increase in risk for breast cancer.
Postmenopausal Hormone Replacement Therapy and the Primary Prevention of Cardiovascular Disease
This systematic review and meta-analysis examined the value of HRT for the primary prevention of CVD, CAD, or both among postmenopausal women and whether bias might explain discordant results between recent trials and the observational literature.
Postmenopausal hormone therapy: new questions and the case for new clinical trials
There is now a critical mass of data to support the hypothesis that age or time since menopause may importantly influence the benefit-risk ratio associated with HT, especially with respect to cardiovascular outcomes, and that the method of administration, dose, and formulation of exogenous hormones may also be relevant.